Suppr超能文献

脓毒性休克中氢化可的松给药频率较低与较高的比较效果

Comparative Effectiveness of Less vs. More Frequent Hydrocortisone Dosing in Septic Shock.

作者信息

Hao Alan, Wu Tianshi David, Collins Keegan, Guffey Danielle, Kessinger Rebecca, Vallabh Meghna, Omranian Ali

机构信息

Department of Pharmacy, Baylor St. Luke's Medical Center, Houston, TX.

Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX.

出版信息

Crit Care Explor. 2025 Sep 15;7(9):e1316. doi: 10.1097/CCE.0000000000001316. eCollection 2025 Sep 1.

Abstract

OBJECTIVES

Guidelines recommend hydrocortisone as an adjunctive treatment in septic shock, but the optimal dosing regimen is unknown. A national shortage of hydrocortisone in 2023 prompted a change in institutional practice for hydrocortisone administration from 50 mg every 6 hours to 100 mg every 12 hours in an effort to reduce waste and conserve vials, creating an opportunity to evaluate the comparative effectiveness of these two regimens. The primary efficacy outcome was time to shock resolution, and secondary outcomes evaluated in this study were mortality, renal replacement therapy (RRT), medication costs, and maximum vasopressor dose attained.

DESIGN

Single-center, retrospective cohort study.

SETTING

ICUs in a quaternary academic medical center.

PATIENTS

Adult patients admitted to an ICU with septic shock, defined by mean arterial pressure less than 65 mm Hg despite adequate fluid resuscitation and need for vasopressor infusion, who were treated with hydrocortisone for shock between October 24, 2022, and October 12, 2023.

INTERVENTIONS

Treatment with hydrocortisone 50 mg every 6 hours or 100 mg every 12 hours.

MEASUREMENTS AND MAIN RESULTS

One hundred thirty-eight patients were included in this retrospective chart review from October 24, 2022, to October 12, 2023. Data for 61 patients in the 50 mg every 6 hours group and 77 patients in the 100 mg every 12 hours group were collected and analyzed. In adjusted competing risk models, hydrocortisone regimen was not associated with differences in time to shock resolution (sub-hazard ratio [sub-HR] 0.95 [95% CI, 0.59-1.54]), ICU mortality (sub-HR 1.59; 95% CI, 0.89-2.84), in-hospital mortality (1.35; 95% CI, 0.81-2.26), or time to RRT (sub-HR 1.01; 95% CI, 0.45-2.31). In addition, the hydrocortisone dose regimen was not associated with differences in maximum vasopressor dose attained (mean difference in norepinephrine equivalent, 0.16 µg/kg/min; 95% CI, -0.26 to 0.58 µg/kg/min). The less frequent dosing resulted in cost savings of $446.10 (95% CI, 253.95-638.25) per patient treated with the more intensive but less frequent hydrocortisone dosing regimen.

CONCLUSIONS

A less frequent hydrocortisone dosing regimen was not associated with differences in time to shock resolution. Studies of the comparative effectiveness of different corticosteroid dosing regimens for septic shock are needed.

摘要

目的

指南推荐氢化可的松作为脓毒性休克的辅助治疗药物,但最佳给药方案尚不清楚。2023年全国范围内氢化可的松短缺,促使机构改变了氢化可的松的给药方式,从每6小时50毫克改为每12小时100毫克,以减少浪费并节省药瓶,从而有机会评估这两种给药方案的相对有效性。主要疗效指标是休克缓解时间,本研究评估的次要指标包括死亡率、肾脏替代治疗(RRT)、药物成本以及达到的最大血管升压药剂量。

设计

单中心回顾性队列研究。

地点

一家四级学术医疗中心的重症监护病房。

患者

入住重症监护病房的成年脓毒性休克患者,定义为尽管进行了充分的液体复苏但平均动脉压仍低于65毫米汞柱且需要血管升压药输注,于2022年10月24日至2023年10月12日期间接受氢化可的松治疗休克。

干预措施

每6小时给予50毫克氢化可的松或每12小时给予100毫克氢化可的松治疗。

测量指标及主要结果

在这项回顾性病历审查中,纳入了2022年10月24日至2023年10月12日期间的138例患者。收集并分析了每6小时50毫克组61例患者和每12小时100毫克组77例患者的数据。在调整后的竞争风险模型中,氢化可的松给药方案与休克缓解时间差异无关(亚风险比[sub-HR]0.95[95%CI,0.59 - 1.54])、重症监护病房死亡率(sub-HR 1.59;95%CI,0.89 - 2.84)、住院死亡率(1.35;95%CI,0.81 - 2.26)或开始肾脏替代治疗的时间差异无关(sub-HR 1.01;95%CI,0.45 - 2.31)。此外,氢化可的松给药方案与达到的最大血管升压药剂量差异无关(去甲肾上腺素等效剂量的平均差异为0.16微克/千克/分钟;95%CI,-0.26至0.58微克/千克/分钟)。给药频率较低的方案使每位接受强度更高但频率较低的氢化可的松给药方案治疗的患者节省成本446.10美元(95%CI,253.95 - 638.25)。

结论

给药频率较低的氢化可的松给药方案与休克缓解时间差异无关。需要开展不同皮质类固醇给药方案治疗脓毒性休克相对有效性的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/611f/12440467/38acbf205699/cc9-7-e1316-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验